Uveitis

Alimera Sciences Reports Second Quarter 2023 Results

Retrieved on: 
Thursday, August 10, 2023
Injection, International, DME, Alimera Sciences, Retinal, EBITDA, Trosia, Acquisition, Patient, Physician, Uveitis, Growth, Adjustment, Recurrence, Video game, Retail, Cryptocurrency

Consolidated Net Revenue of $17.5 Million Up 20% vs. Second Quarter of 2022

Key Points: 
  • Consolidated Net Revenue of $17.5 Million Up 20% vs. Second Quarter of 2022
    Global End User Demand for ILUVIEN Up 13.5% vs. Second Quarter of 2022
    ATLANTA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the second quarter of 2023.
  • The transaction has provided immediate results, despite planned costs of combining the two products in our infrastructure, contributing to the generation of positive Adjusted EBITDA in the second quarter,” said Rick Eiswirth, Alimera’s President and Chief Executive Officer.
  • In addition, YUTIQ generated an additional 440 units of end user demand in the second quarter from the date of acquisition in late May.
  • As of June 30, 2023, Alimera had cash and cash equivalents of approximately $18.8 million, compared to $13.1 million at March 31, 2023.

First Patient Enrolled in LEOPARD, an Investigator-Initiated Trial, with OCS-01 Eye Drops for the Treatment of Cystoid Macular Edema

Retrieved on: 
Wednesday, August 2, 2023
CME, Diabetes, DME, Seven Years in Tibet (song), Cataract, CRST, OCS, Risk, Diabetic retinopathy, Inflammation, MUST, Cerebral edema, Dexamethasone, Pain, Stanford University School of Medicine, Patient, PSME, CST, Master of Science, Uveitis, Macular edema, Paratriathlon, Visual acuity, UME, Safety, Pharmaceutical industry, Ophthalmology, CME2, MD

CME may occur as a complication of ocular conditions, including uveitis and ocular surgery, and is a leading cause of vision loss worldwide.

Key Points: 
  • CME may occur as a complication of ocular conditions, including uveitis and ocular surgery, and is a leading cause of vision loss worldwide.
  • It is one of the most significant causes of postoperative vision loss after cataract surgery1.
  • CME is being explored with OCS-01 eye drops, in addition to diabetic macular edema (DME) and inflammation and pain post ocular surgery, both indications currently in Phase 3 clinical development.
  • Seven-year outcomes of uveitic macular edema: the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study results, Ophthalmology, May 2021 128 (5): 719-728 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943640/

RetinalGeniX Technologies Inc. Granted Patent for Patient Home Monitoring and Physician Alert System for Ocular Anatomy

Retrieved on: 
Friday, July 28, 2023
Retina, Glaucoma, Diabetes, Arthritis, Eye, Ophthalmology, OTCQB, Brain, Cataract, Paratriathlon, Risk, Uveitis, Optometry, Blood, Maculopathy, Patent, MD, Patient, Physician, Systemic disease, Diagnosis, Diabetic retinopathy, Health, Nursing, Medical device, Medical imaging

PETALUMA, Calif., July 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), this week was granted a patent for its Patient Home Monitoring and Integrated Physician Alert System For Ocular Anatomy.

Key Points: 
  • PETALUMA, Calif., July 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), this week was granted a patent for its Patient Home Monitoring and Integrated Physician Alert System For Ocular Anatomy.
  • The current model of eye care, in which patients schedule in-person visits with eye specialists suffers from many drawbacks.
  • Ocular screening is important because, when a patient has diabetes, the earliest observable change to the body is in the eyes.
  • Katzman continued, "In light of the severe shortage of healthcare professionals, remote diagnostic technology is essential for efficient patient management.

SightMD Connecticut Welcomes Shimy Apoorva, DO to its expert team

Retrieved on: 
Monday, July 17, 2023
Glaucoma, TRI, Keratitis, CT, Office management, Saint John's, AMD, Medicine, Cataract, Uveitis, American Academy of Ophthalmology, St. John's Episcopal Hospital South Shore, Gardening, Osteopathy, Walking, American Osteopathic Association, Bullous pemphigoid, Patient, Cooking, Physician, Diagnosis, Diabetic retinopathy, Health, Family, Scleritis, Ophthalmology, Growth

HAUPPAUGE, N.Y., July 17, 2023 /PRNewswire-PRWeb/ -- SightMD Connecticut, a leading multi-specialty ophthalmology platform in Connecticut, welcomes Shimy Apoorva, DO to its expert team.

Key Points: 
  • SightMD Connecticut, a leading multi-specialty ophthalmology platform in Connecticut, welcomes Shimy Apoorva, DO to its expert team.
  • HAUPPAUGE, N.Y., July 17, 2023 /PRNewswire-PRWeb/ -- SightMD Connecticut, a leading multi-specialty ophthalmology platform in Connecticut, welcomes Shimy Apoorva, DO to its expert team.
  • Dr. Apoorva earned a doctorate of osteopathic medicine in 2017 from Philadelphia college of osteopathic medicine, Suwanee Georgia.
  • Upon completing her medicine training Dr. Apoorva completed her TRI and ophthalmology residency from St. John's Episcopal Hospital Far Rockaway, NY.

Alumis Announces Expansion of Allosteric TYK2 Inhibitor, ESK-001, Phase 2 Program into Systemic Lupus Erythematosus (SLE) and Uveitis

Retrieved on: 
Thursday, June 29, 2023
Sarcoidosis, Lupus, Week, Eye, Clinical trial, Pharmacokinetics, NIU, Multifocal choroiditis and panuveitis, SLE, Uveitis, Rheumatoid arthritis, Psoriasis, Inflammatory bowel disease, Patient, Uvea, SAN, TYK2, Cytokine, STRIDE, Safety, Disease, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Alumis Inc., a clinical stage biopharmaceutical company developing oral therapies using a precision approach to transform the lives of patients with immune-mediated diseases, today announced that patient dosing has commenced in LUMUS, a Phase 2b clinical trial of ESK-001 for the treatment of patients with systemic lupus erythematosus (SLE) and in OPTYK-1, a proof-of-concept Phase 2 clinical trial in uveitis. SLE is a chronic immune-mediated disease involving multiple organs. ESK-001 is Alumis’ proprietary lead clinical candidate and is a highly selective and potentially best-in-class allosteric tyrosine kinase 2 (TYK2) inhibitor.

Key Points: 
  • ESK-001 is Alumis’ proprietary lead clinical candidate and is a highly selective and potentially best-in-class allosteric tyrosine kinase 2 (TYK2) inhibitor.
  • “ESK-001 is a highly selective allosteric inhibitor of TYK2 that demonstrated full, sustained target inhibition and was well tolerated in Phase 1 studies of healthy volunteers.
  • British-Isles Lupus Assessment Group (BILAG)-based Combined Lupus Assessment (BICLA) is an accepted composite measure of overall SLE disease activity.
  • Alumis continues to leverage its precision data analytics and a multi-platform approach to explore ESK-001’s potential application in other autoimmune indications.

EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties

Retrieved on: 
Thursday, May 18, 2023
Drug development, Therapy, SG, DME, Marketing, Calendar, Eye, Diabetic retinopathy, Sale, Alimera Sciences, Patient, Uveitis, Safety, Pharmaceutical industry, Trosia

WATERTOWN, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that it has entered into a definitive agreement for the sale of YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18mg to Alimera Sciences, Inc. (“Alimera”). YUTIQ is a treatment for chronic non-infectious uveitis affecting the posterior segment of the eye. Under the terms of the agreement, Alimera will receive global rights to YUTIQ outside of China, Hong Kong, Taiwan, Macau and Southeast Asia, where YUTIQ is exclusively licensed to Ocumension Therapeutics (“Ocumension”), and EyePoint will continue to receive royalties from Ocumension for its YUTIQ sales. In exchange for the rights granted to Alimera under the agreement, EyePoint received a $75 million up-front cash payment at closing and will receive an additional $7.5 million in equal quarterly installments in 2024. In addition, commencing in 2025, EyePoint will receive a low to mid double-digit royalty on Alimera’s related U.S. net sales above defined thresholds for the calendar years 2025-2028.

Key Points: 
  • YUTIQ is a treatment for chronic non-infectious uveitis affecting the posterior segment of the eye.
  • In exchange for the rights granted to Alimera under the agreement, EyePoint received a $75 million up-front cash payment at closing and will receive an additional $7.5 million in equal quarterly installments in 2024.
  • In addition, commencing in 2025, EyePoint will receive a low to mid double-digit royalty on Alimera’s related U.S. net sales above defined thresholds for the calendar years 2025-2028.
  • EyePoint and Alimera are committed to ensuring that patients receive uninterrupted access to YUTIQ throughout the transition of YUTIQ sales, marketing and other responsibilities to Alimera.

Alimera Acquires U.S. Commercial Rights to YUTIQ®

Retrieved on: 
Thursday, May 18, 2023
Trade, University, Alimera Sciences, Eye, NLRP3, SOFR, Sun Pharma, Sale, Strategic management, EBITDA, Patient, Physician, Acquisition, Uveitis, Growth, Security (finance), Commercial, Therapy, Conference, Pharmaceutical industry, Video game, Management, Bank, Inflammasome, Trosia, Series

**

Key Points: 
  • **
    Alimera now has exclusive global rights to YUTIQ excluding China, Hong Kong, Taiwan, Macau, South Korea and Southeast Asia, where EyePoint has a pre-existing license with Ocumension Therapeutics.
  • “We deeply appreciate the support of SLR Capital and our new shareholders with this transformative transaction for Alimera,” continued Mr. Eiswirth.
  • In conjunction with these transactions, Alimera has added Jason Werner to its Board of Directors, as a designee of Velan Capital.
  • All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call.

SightMD Physicians named 2023 Super Doctors® and Rising Stars

Retrieved on: 
Monday, May 15, 2023
Medicine, Editorial board, Paratriathlon, DO, MD, Patient, Premature, Neuro-ophthalmology, Forehead, World Golf Village, Corneal transplantation, Face, Friends, Orbit, Research, Rockville Centre, New York, Super, Uveitis, Optic nerve, Entrepreneurship, New York Eye and Ear Infirmary, Textbook, Cataract, Abstract, Osteopathic medicine in the United States, Good Samaritan Hospital, Eye, Eyelid, Publishing, Clinical research, Engineering, Microsurgery, Family, Surgeon, CXL, Education, Cross-link, Physician, Hall, Fellow, Pleasure, Rare-earth element, Medical device, Nursing, Dentistry, Veterinary medicine, Ophthalmology, Glaucoma, PRK, Retina, LASIK

HAUPPAUGE, N.Y., May 15, 2023 /PRNewswire-PRWeb/ -- SightMD is excited to announce the growing list of providers that have been named on the 2023 "Super Doctor" and "Super Doctors Rising Stars" lists.

Key Points: 
  • SightMD is excited to announce the growing list of providers that have been named on the 2023 "Super Doctor" and "Super Doctors Rising Stars" lists.
  • HAUPPAUGE, N.Y., May 15, 2023 /PRNewswire-PRWeb/ -- SightMD is excited to announce the growing list of providers that have been named on the 2023 "Super Doctor" and "Super Doctors Rising Stars" lists.
  • said Dr. Baharestani "It is an honor to provide our patients with the highest level oculoplastic surgery services at SightMD."
  • "I am truly honored to be selected as a Super Doctors Rising Star for the 5th year in a row."

ELITE PARATRIATHLETE AMY DIXON WILL DELIVER KEYNOTE AT GLAUCOMA RESEARCH FOUNDATION'S 2023 PATIENT SUMMIT

Retrieved on: 
Thursday, May 4, 2023
GRF, Glaucoma, Tokyo Paralympics, Hope, Weight gain, Running, Swimming, Patient, France 4 Visionary Award, SAN, Uveitis, Gold medal, Autoimmune disease, Paratriathlon, Caregiver, Female, Television

SAN FRANCISCO, May 4, 2023 /PRNewswire/ -- Glaucoma Research Foundation (GRF), a national non-profit organization dedicated to finding a cure for glaucoma, has selected visually impaired professional triathlete Amy Dixon as keynote speaker for its 2023 Patient Summit, to be held in Long Beach, California, June 23-24.

Key Points: 
  • SAN FRANCISCO, May 4, 2023 /PRNewswire/ -- Glaucoma Research Foundation (GRF), a national non-profit organization dedicated to finding a cure for glaucoma, has selected visually impaired professional triathlete Amy Dixon as keynote speaker for its 2023 Patient Summit, to be held in Long Beach, California, June 23-24.
  • In addition to an elite paratriathlete, Dixon is a dedicated patient advocate and motivational speaker, spreading awareness and hope as she competes around the world.
  • "Patients inspire and drive the work at Glaucoma Research Foundation, each and every day," said Thomas Brunner, GRF President and CEO.
  • This will be the fifth year for GRF's Glaucoma Patient Summit, which brings hundreds of patients, caregivers, and glaucoma experts together in a unique supportive community.

Tarsier Pharma announces International Non-proprietary Name for TRS

Retrieved on: 
Monday, April 24, 2023
Glaucoma, Intraocular pressure, IOP, International, TRS, World Health Organization, TEL, Ocular hypertension, Patient, Risk, Uveitic glaucoma, Uveitis, Tarsier, Steroid, WHO, Paratriathlon, Safety, Generic drug, Pharmaceutical industry

TEL AVIV, Israel, April 24, 2023 /PRNewswire/ -- Tarsier Pharma Ltd., a late-stage pharmaceutical company, announced today that its first-in-class immunomodulator TRS has been granted an International Nonproprietary Name (INN) of 'Dazdotuftide"' and has been placed on the INN Recommended List by the World Health Organization (WHO).

Key Points: 
  • TEL AVIV, Israel, April 24, 2023 /PRNewswire/ -- Tarsier Pharma Ltd., a late-stage pharmaceutical company, announced today that its first-in-class immunomodulator TRS has been granted an International Nonproprietary Name (INN) of 'Dazdotuftide"' and has been placed on the INN Recommended List by the World Health Organization (WHO).
  • "Achieving an INN- Dazdotuftide is another milestone in our journey to bring TRS to patients in need.
  • We are in exciting times, as we are wrapping up the first comprehensive, multi-center, global phase 3 clinical trial and expecting results by the third quarter of this year," said Daphne Haim-Langford, CEO of Tarsier Pharma.
  • Tarsier is developing TRS as an eye drop formulation (TRS01) and as slow-release biodegradable intravitreal injections (TRS02) targeting back-of-the-eye indications with an underlying inflammatory pathology, such as Diabetic Macular Edema, Non-Proliferative Diabetic Retinopathy, and others.